Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

Koji Sasaki, Elias J. Jabbour, Farhad Ravandi, Nicholas J. Short, Deborah A. Thomas, Guillermo Garcia-Manero, Naval G. Daver, Tapan M. Kadia, Marina Y. Konopleva, Nitin Jain, Ghayas C. Issa, Vicki Jeanis, Haim G. Moore, Rebecca S. Garris, Naveen Pemmaraju, Jorge E. Cortes, Susan M. O'Brien, Hagop M. Kantarjian

Research output: Contribution to journalArticlepeer-review

107 Scopus citations

Fingerprint

Dive into the research topics of 'Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences